Cadrenal Therapeutics Rings the Nasdaq Stock Market Closing Bell
Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company focused on developing tecarfarin, a clinical-stage novel cardiorenal therapy with orphan drug and Fast Track designations, visits the Nasdaq MarketSite in Times Square. In honor of the occasion, Quang Pham, Chairman and CEO, rings the Closing Bell.